Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2010

View Archived Issues

4-PBA and curcumin enhance protein expression of mutant ATP7B / News in Context

Genzyme reports 2-year data from phase II Gaucher's disease trial

Bristol-Myers Squibb reports results from fourth quarter 2009, ended December 31

Shionogi files additional application in Japan for pediatric use of Rapiacta

Oxigene presents update on development of Zybrestat

3SBio submits application in China for phase I clinical trial of NuPIAO

Debiopharm's Clinical Trial Application for Debio-0932 approved in France

Helix reports preliminary results from phase II study of topical interferon alpha-2b

ADX-71943 demonstrates analgesic effects in preclinical pain models

Repros submits response to FDA regarding Androxal in hypogonadism

LJ-001, a broad-spectrum antiviral targeting the viral lipid membrane

Solvay claims novel adenosine A1 receptor antagonists

Amakem starts operations to discover and develop novel kinase inhibitors

Bristol-Myers Squibb claims MAP kinase inhibitors for inflammatory disorders

Millennium Pharmaceuticals patents novel proteasome inhibitors

Older vaccines provide protection against 2009 pandemic H1N1 influenza

Genentech identifies new Janus kinase inhibitors

Roche claims monoamine reuptake inhibitors for the treatment of affective disorders

HDAC inhibitor SAHA restores activity of mutant CFTR in vitro

Fingolimod shows clinical benefit in two phase III trials in relapsing-remitting MS

AVI BioPharma receives grants for Duchenne muscular dystrophy drug development

Toyama initiates U.S. phase II trial for its anti-influenza drug candidate, T-705

Abbott acquires Solvay Pharmaceuticals for EUR 4.5 billion

AstraZeneca and Rigel sign license agreement for fostamatinib disodium in RA

Pharmaxis completes phase I clinical trial of PXS-25 in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...